XML 42 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Shareholders Equity Shareholders' Equity (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Jan. 01, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance     $ 8,088.8       $ 8,088.8    
Net loss $ (197.5)     $ (142.9)     21.8 $ (433.5)  
Shares issued under share-based compensation plans, net         3,400,000        
Distributions to noncontrolling interests       (2.0) $ (0.7)        
Net other comprehensive income (1.0)     $ (1.3)     0.7 $ (10.2)  
Ending balance $ 9,530.5           $ 9,530.5    
Common Stock                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance (in shares) 205,800,000 115,200,000 115,200,000 115,200,000 111,800,000 111,800,000 115,200,000 111,800,000  
Beginning balance $ 82.5 $ 46.2 $ 46.2 $ 46.2 $ 44.8 $ 44.8 $ 46.2 $ 44.8  
Equity issuance in connection with the Rowan Transaction   $ 35.2              
Equity issuance in connection with the Rowan Transaction (in shares)   88,000,000.0              
Shares issued under share-based compensation plans, net   2,600,000              
Shares issued under share-based compensation plans, net   $ 1.1     $ 1.4        
Ending balance (in shares) 205,800,000 205,800,000 115,200,000 115,200,000 115,200,000 111,800,000 205,800,000 115,200,000  
Ending balance $ 82.5 $ 82.5 $ 46.2 $ 46.2 $ 46.2 $ 44.8 $ 82.5 $ 46.2  
Additional Paid-in Capital                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance 8,608.4 7,230.2 7,225.0 7,209.5 7,202.4 7,195.0 7,225.0 7,195.0  
Equity issuance in connection with the Rowan Transaction (0.6) 1,365.5              
Shares issued under share-based compensation plans, net   (1.1) (0.1)   (0.4) (0.1)      
Repurchase of shares       0.1          
Share-based compensation cost 9.7 13.8 5.3 7.2 7.5 7.5      
Ending balance 8,617.5 8,608.4 7,230.2 7,216.6 7,209.5 7,202.4 8,617.5 7,216.6  
Retained Earnings                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance 1,084.8 679.3 874.2 1,232.0 1,387.4 1,532.7 874.2 1,532.7  
Net loss (197.1) 405.5 (190.4) (145.0) (151.0) (140.1)      
Dividends paid     (4.5) (4.5) (4.4) (4.4)      
Ending balance 887.7 1,084.8 679.3 1,082.5 1,232.0 1,387.4 887.7 1,082.5  
Retained Earnings | Accounting Standards Update 2018-02                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Cumulative-effect due to ASU 2018-02                 $ (0.8)
AOCI Attributable to Parent                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance 19.9 19.7 18.2 20.5 29.0 28.6 18.2 28.6  
Net other comprehensive income (1.0) 0.2 1.5 (1.3) (8.5) (0.4)      
Ending balance 18.9 19.9 19.7 19.2 20.5 29.0 18.9 19.2  
AOCI Attributable to Parent | Accounting Standards Update 2018-02                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Cumulative-effect due to ASU 2018-02                 $ 0.8
Treasury Stock                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance (75.0) (74.9) (72.2) (72.0) (70.0) (69.0) (72.2) (69.0)  
Equity issuance in connection with the Rowan Transaction   2.1              
Shares issued under share-based compensation plans, net   (0.8) 0.1   (1.4) 0.1      
Repurchase of shares 0.2 1.4 2.8 0.1 0.6 1.1      
Ending balance (75.2) (75.0) (74.9) (72.1) (72.0) (70.0) (75.2) (72.1)  
Noncontrolling Interest                  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Beginning balance 1.6 (0.2) (2.6) (2.3) (2.5) (2.1) (2.6) (2.1)  
Net loss (0.4) 1.8 2.4 2.1 0.9 (0.4)      
Distributions to noncontrolling interests (2.1)                
Ending balance $ (0.9) $ 1.6 $ (0.2) $ (2.2) $ (2.3) $ (2.5) $ (0.9) $ (2.2)